Amgen 2011 Annual Report Download - page 52

Download and view the complete annual report

Please find page 52 of the 2011 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 184

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184

Results from a phase 2 study in gastric cancer in combination with chemotherapy were reported at a
meeting in September 2011. Phase 2 combination studies in the prostate and small cell lung cancer settings
continue.
As of February 9, 2011, we had nine phase 3 programs. As of February 10, 2012, we had twelve phase 3
programs, as one was added as the result of our BioVex acquisition and two programs had advanced into phase 3
trials. These changes are set forth in the following table:
Molecule Disease / Condition Program Change
Talimogene laherparepvec Malignant melanoma Added through acquisition of BioVex
Sensipar®/ Mimpara®(cinacalcet) Post Renal Transplant Advanced to Phase 3
Aranesp®(darbepoetin alfa) Myelodysplastic syndromes Advanced to Phase 3
Phase 3 Product Candidate Patent Information
Our outstanding patents for each of our product candidates in phase 3 development that have yet to be
approved for any indication are described in the following table. Patents for products already approved for one or
more indications but currently undergoing phase 3 clinical trials for additional indications are previously
described. (See Marketed Products.)
Molecule Territory General Subject Matter Estimated Expiration*
AMG 386 U.S.
Europe
DNA, polypeptides and compositions
DNA, polypeptides, compositions and method of
treatment
2025
2019-2022
Ganitumab U.S. Antibodies and compositions 2029
Motesanib U.S.
Europe
Motesanib and compositions
Motesanib, compositions and use for treatment of
cancer
2022
2022
Talimogene laherparepvec U.S. Modified HSV1 compounds and strains and
methods of treatment using modified HSV1
strains
2021
Europe Modified HSV1 compounds and strains and
methods of treatment using modified HSV1
strains
2021
* Patent expiration ranges for each region are based on one or more issued patents, some of which may be or
become eligible for term adjustments, extensions or supplemental protection certificates not captured in this
estimate. In addition, new patents may be issued in the future, and existing patents may be challenged,
invalidated or circumvented by third parties.
Business Relationships
From time to time, we enter into business relationships, including joint ventures and collaborative
arrangements, for the R&D, manufacture and/or commercialization of products and/or product candidates. In
addition, we also acquire product and R&D technology rights and establish R&D collaborations with third parties
to enhance our strategic position within our industry by strengthening and diversifying our R&D capabilities,
product pipeline and marketed product base. These arrangements generally provide for non-refundable upfront
license fees, regulatory and commercial performance milestone payments, cost sharing, royalty payments and/or
profit sharing. The activities under our collaboration agreements are performed with no guarantee of either
technological or commercial success, and each is unique in nature.
36